Scholar Rock Holding (SRRK) Income from Continuing Operations (2017 - 2026)
Scholar Rock Holding's (SRRK) quarterly Income from Continuing Operations came in at 101449000.0 in Q1 2026, down 35.42% year-on-year from 157100723.27 in Q1 2025, and down 13.37% quarter-over-quarter from 89484000.0 in Q4 2025.
Scholar Rock Holding (SRRK) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 101449000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 35.42% year-over-year to 101449000.0 in Q1 2026; TTM through Mar 2026 was 715227000.0, a 166.34% decrease from a year earlier, with the FY2025 full-year figure at 377734000.0, down 53.37% from the prior year.
- Income from Continuing Operations declined to 101449000.0 in Q1 2026 per SRRK's latest filing, from 89484000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 9196000.0 in Q1 2022 and bottomed at 263834000.0 in Q2 2025.
- The 5-year median for Income from Continuing Operations is 56832000.0 (2024), against an average of 80241882.35.
- Across the five-year window, Income from Continuing Operations soared 93.69% in 2022 and sank 383.1% in 2023, its largest moves.
- Year by year, Income from Continuing Operations stood at 41768000.0 in 2022, then fell by 18.96% to 49688000.0 in 2023, then plunged by 36.16% to 67656000.0 in 2024, then sank by 32.26% to 89484000.0 in 2025, then declined by 13.37% to 101449000.0 in 2026.
- Per Business Quant, the three latest SRRK Income from Continuing Operations figures stand at 101449000.0 (Q1 2026), 89484000.0 (Q4 2025), and 260460000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Scholar Rock Holding | 6.10 Bn | 6.10 Bn | - | -101.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -101.45 Mn |
| Dec 31, 2025 | -89.48 Mn |
| Sep 30, 2025 | -260.46 Mn |
| Jun 30, 2025 | -263.83 Mn |
| Mar 31, 2025 | -74.91 Mn |
| Dec 31, 2024 | -67.66 Mn |
| Sep 30, 2024 | -65.66 Mn |
| Jun 30, 2024 | -60.31 Mn |
| Mar 31, 2024 | -56.83 Mn |
| Dec 31, 2023 | -49.69 Mn |
| Sep 30, 2023 | -46.00 Mn |
| Jun 30, 2023 | -42.09 Mn |
| Mar 31, 2023 | -44.43 Mn |
| Dec 31, 2022 | -41.77 Mn |
| Sep 30, 2022 | -46.45 Mn |
| Jun 30, 2022 | -43.90 Mn |
| Mar 31, 2022 | -9.20 Mn |
| Dec 31, 2021 | -35.95 Mn |
| Sep 30, 2021 | -87.69 Mn |
| Jun 30, 2021 | -77.06 Mn |